| Esperion Therapeutics is a pharmaceutical company that develops and commercializes oral, once-daily, non-statin medicines for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). Co.'s primary products, NEXLETOL tablet and NEXLIZET tablets, are oral, once-daily, non-statin LDL-C lowering medicines approved in the U.S. for patients with atherosclerotic cardiovascular disease (ASCVD) or heterozygous familial hypercholesterolemia (HeFH). The U.S. Food and Drug Administration has approved NEXLETOL as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with HeFH or established ASCVD who require additional lowering of LDL-C. We show 22 historical shares outstanding datapoints in our ESPR shares outstanding history coverage, used to compute ESPR market cap on those dates.|
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing ESPR market cap history over the course of time is important for investors
interested in comparing ESPR's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of ESPR versus a peer is one thing; comparing
ESPR market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like ESPR can fluctuate over the course of history.
With this page we aim to empower investors researching ESPR by allowing them to research the ESPR market cap history.